Table 1: Individual characteristics and group summary for participants with PD and summary for HOA and HYA groups.

AgePD durationSexMDS-UPDRSH & YMoCAMedications (LED)

PD-1016613M32229Carbidopa/levodopa, pramipexole (256)
PD-102677F21226Carbidopa/levodopa, pramipexole, selegiline (204)
PD-103773M41227Carbidopa/levodopa (63)
PD-1046217F47226Carbidopa/levodopa, entacapone, amantadine, ropinirole (958)
PD-105726F18327Carbidopa/levodopa, rasagiline (163)
PD-106664F9129Rasagiline, pramipexole (125)
PD-107789M31222Carbidopa/levodopa, pramipexole (525)
PD-108812M46227Carbidopa/levodopa (75)
PD-109707M57230Carbidopa/levodopa, pramipexole (450)
PD-110708F18225Carbidopa/levodopa (200)
PD-111834M22229Carbidopa/levodopa (150)
PD-112796M49323Carbidopa/levodopa, amantadine (425)
PD-113714M38228Ropinirole (160)
PD-114681M25229Selegiline (100)
PD-115731F23329Carbidopa/levodopa (125)

PD
mean (SD)
range
72.2 (6.2)
62–83
6.1 (4.4)6 F/9 M32 (14)
9–57
2.1 (1.5)
1–3
27.1 (2.3)
22–30
265 (238)

HOA
mean (SD)
range
69.2 (7.1)
60–80
10 F/5 M28.5 (1.7)
24–30

HYA
mean (SD)
range
26.4 (4.3)
20–36
9 F/6 M

Age and PD duration in years. MDS-UPDRS: Movement Disorders Society Unified Parkinson’s Disease Rating Scale, motor examination. H & Y: Hoehn and Yahr rating scale. MoCA: Montreal Cognitive Assessment. LED: levodopa equivalent dosage. SD: standard deviation.